Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022

Global Cystic Fibrosis Therapeutics Market is poised for subnational growth inside the coming years, in keeping with Renub Research. With a projected CAGR of 14.40% for the duration of 2022-2028, the marketplace is predicted to reach US$ 24.35 billion via 2028. Cystic fibrosis therapeutics embody a variety of medication, including CFTR modulators and gene remedy, offering tailored remedy alternatives to manage the signs of a genetic disease affecting the respiratory and digestive systems. By correcting the underlying genetic disorder chargeable for CF and improving the characteristic of the CFTR protein, those therapeutics contribute to a higher great of life by coping with signs and symptoms and slowing ailment development.

The demand for cystic fibrosis therapeutics is predicted to surge substantially over the forecast period due to the growing occurrence of CF and growing treatment cost. The growth within the cystic fibrosis (CF) marketplace can be driven by the ongoing uptake of costly Trikafta/Kaftrio and label growth to a developing population of CF patients, the release of VX-121 + tezacaftor + VX-561 (deutivacaftor) in 2025 inside the US and 2026 within the 5EU, an expensive subsequent-technology triple combination, and the launch of VX-561 (deutivacaftor) in 2025 in the US and 2026 inside the 5EU.


The market for cystic fibrosis therapeutics is expected to be bolstered by a surge in initiatives undertaken by nonprofit organizations, a substantial increase in R&D funding by private and public organizations, and favorable reimbursement policies. Moreover, the primary critical players in the Global Cystic Fibrosis Therapeutics Market, including Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, and AstraZeneca, are expected to play a crucial role in driving the growth of the market.

Request a free sample copy of the report:

However, the market has its challenges. The slow reimbursement for novel CFTR modulators in some 5EU countries and Canada decreased usage of symptomatic drug classes such antibiotics, mucolytics, and anti-inflammatory drugs due to overall improvements to lung health following the use of Trikafta/Kaftrio, lack of novel products entering the CF market in the mucolytic or inhaled drug class, and low patient compliance due to the high treatment burden are significant barriers to market growth.

Market Summary

Route of Administration – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 2 Viewpoints: Oral and inhaled.

Treatment – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 3 Viewpoints (Medication, Devices, Other Treatment)

Test Type – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 5 Viewpoints: Pulmonary Function, Sweat Calories, IRT Test, Faceal Tests, and Genetic Tests.

Distribution – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 3 Viewpoints: Hospitals, Retail Pharmacies, and Others.

Drug Class – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 4 Viewpoints: Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, and CFTR Modulators.

Region – Cystic Fibrosis Therapeutics Market Analysis has been Covered from 5 Viewpoints: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

All companies have been covered from 3 viewpoints:

  • Overviews
  • Recent Developments
  • Revenues


  1. Vertex Pharmaceuticals
  2. Abbvie Inc.
  3. Novartis Ag
  4. Gilead Sciences
  5. Viatris INC
  6. Pfizer
  7. AstraZeneca

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)




What's your reaction?

In Love
Not Sure

You may also like

More in:Business

Comments are closed.